Vernalis Research

We are a world leader in structure- and fragment-based drug discovery. We have generated six development candidates in the past seven years and cell active lead compounds against 15 different targets. Our successes include projects in close collaboration with companies such as Lundbeck, Novartis, Servier, Genentech, Asahi Kasei Pharma and Taisho. Our strengths are in developing and applying the most appropriate structure-based methods to work with our partners to solve problems in drug discovery.



Latest News

Results Announcement for the 12 months ended 30 June 2016

Vernalis plc (LSE: VER) today announces its audited results for the 12 month period ended 30 June 2016.

Read more ...

Product Pipeline

For more information on our pipeline, click below to visit Vernalis plc

Commercial Pipeline

Comm-thumbnailExplore the pipeline ...


NCE Pipeline

NCE-thumbnailExplore the pipeline ...


Contact Vernalis Research

T: (0)1223 895555
F: (0)1223 895556

Contact information
Maps and directions
Contact form

Fact Sheet

For more information on Vernalis, click on the below image to download a copy of our fact sheet

Vernalis Factsheet May 2015 Page 1